Amarin Corp. PLC (AMRN) Trading Down 2%
Shares of Amarin Corp. PLC (NASDAQ:AMRN) fell 2% during mid-day trading on Friday . The company traded as low as $3.01 and last traded at $3.01, with a volume of 919,753 shares trading hands. The stock had previously closed at $3.07.
A number of research firms have recently issued reports on AMRN. Jefferies Group reaffirmed a “buy” rating on shares of Amarin Corp. PLC in a research report on Tuesday, May 31st. Zacks Investment Research cut Amarin Corp. PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, May 17th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Amarin Corp. PLC in a report on Monday, May 9th.
The firm has a 50 day moving average of $2.76 and a 200-day moving average of $2.00. The stock’s market capitalization is $568.42 million.
Amarin Corp. PLC (NASDAQ:AMRN) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.06. The firm had revenue of $32.82 million for the quarter, compared to analyst estimates of $29.97 million. During the same period last year, the company posted ($0.15) earnings per share. The firm’s quarterly revenue was up 85.4% compared to the same quarter last year. Equities analysts predict that Amarin Corp. PLC will post ($0.46) earnings per share for the current year.
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.